Work

Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

Year: 2024

Type: article

Study design: Clinical Trial

Source: Prostate Cancer and Prostatic Diseases

DOI: 10.1038/s41391-024-00811-5

Authors: Ryan E. Fecteau, Bridget F. Koontz, Karen E. Hoffman, Susan Halabi, Lauren E. Howard, Monika Anand, Daniel J. George, Tian Zhang, William R. Berry, W. Robert Lee, Michael R. Harrison, Paul G. Corn, Andrew J. Armstrong

Institutions: Duke University, Duke Cancer Institute, East Carolina University, The University of Texas MD Anderson Cancer Center, Duke Medical Center, The University of Texas Southwestern Medical Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: U.S. Department of Defense, Janssen Pharmaceuticals

Awards: G5278695764, CLINICAL CONSORTIUM: CLINICAL RESEARCH SITE

OpenAlex ID: W4392049335

FWCI: 0.289

Cites: 9

Cited by: 1

Related to: 10